Loading
Antibodies, Monoclonal / Tumor Microenvironment / Neoplasms · Journal article
Cancer Biology & Therapy · July 28, 2026
Raises a question worth testing. It does not answer one.
This is a structured narrative review synthesizing the proposed molecular interplay between insulin resistance and cancer, identifying multiple signaling pathways (PI3K-Akt-mTOR, MAPK, JAK-STAT, NF-κB) and immune checkpoints potentially amenable to monoclonal antibody intervention. The work is conceptual and proposes a rationale for targeting IGF-1R, IL-6, IL-1β, TNF-α, PD-1, PD-L1, and CTLA-4, but presents no trial data, efficacy metrics, or comparative evidence.
Structured narrative review. Patients with insulin resistance and cancer (general population; no specific cohort studied).
Insulin resistance contributes to hyperinsulinemia, IGF signaling disruption, chronic inflammation, and metabolic remodeling that foster a pro-tumorigenic milieu. IR-associated changes stimulate PI3K-Akt-mTOR, MAPK, JAK-STAT, and NF-κB pathways, increasing proliferation, survival, angiogenesis, immune escape, and metastasis. IR modifies the tumor microenvironment and dampens anti-tumor immunity.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides a mechanistic framework for understanding how insulin resistance may promote cancer and suggests potential antibody-based interventions; however, without primary efficacy data or clinical trial results, it should be read as hypothesis-generating rather than practice-guiding. Clinicians should await prospective evidence before incorporating these targets into treatment decisions.
This is a narrative review proposing mechanistic connections between insulin resistance and cancer, with speculative discussion of monoclonal antibody therapeutics, but no primary experimental or clinical data to support efficacy claims.
As stated by the source record.
This review provides a mechanistic framework for understanding how insulin resistance may promote cancer and suggests potential antibody-based interventions; however, without primary efficacy data or clinical trial results, it should be read as hypothesis-generating rather than practice-guiding. Clinicians should await prospective evidence before incorporating these targets into treatment decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Insulin resistance (IR) is involved in the development, progression, and treatment resistance of cancer. Apart from contributing to obesity and type 2 diabetes, IR leads to hyperinsulinemia, disruption of insulin-like growth factor signaling, chronic inflammation, and metabolic remodeling, which fosters a pro-tumorigenic milieu. These changes stimulate the PI3K-Akt-mTOR, MAPK, JAK-STAT, and NF-κB pathways, which increase proliferation, survival, angiogenesis, immune escape, and metastasis. IR also modifies the tumor microenvironment (TME) and dampens anti-tumor immunity. IGF-1R, IL-6, IL-1β, TNF-α, PD-1, PD-L1, and CTLA-4 monoclonal antibodies could be beneficial by inhibiting inflammatory and oncogenic pathways and reinitiating immune surveillance. Tumor resistance and heterogeneity are significant obstacles. This is a structured narrative review of the molecular connections, antibody treatments, translational obstacles, and future refined approaches in oncology.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.